本研究指出台灣樣本生物技術醫療公司生產力指數effch、techch、pech、sech及tfpch,全期間之平均值分別為0.786、1.005、1.000、1.001及1.006。代表在估計期間,受評估台灣上市生技醫療公司是有0.6%(=1.006-1)的生產面生產力改善。在估計期間,受評估生技醫療公司生產面總要素生產力指數(tfpch)前10名的公司為4123 晟德、6499 益安、6461 益得、4168 醣聯、4147 中裕、4162 智擎、8436 大江、6242 立康、4726 永昕、1799 易威。受評估台灣上市生技醫療公司之生產面生產力指數tfpch與其股價關係為正向顯著關係。
This paper pointed out that Taiwan's biotechnology medical company productivity index effch, techch, pech, sech and tfpch, the average value of the whole period were 0.786, 1.005, 1.000, 1.001 and 1.006. During the estimation period, the representative of Taiwan-listed biotech companies was 0.6% (=1.006-1) with improved production productivity. During the estimation period, the top 10 companies in the estimated total production factor productivity index (tfpch) of the biotechnology medical company were 4123 Jude, 6499 Yi'an, 6461 Yi De, 4168 Sugar Link, 4147 Zhongyu, 4162 Zhiqing, 8436 Dajiang, 6242 Likang, 4726 Yongzheng, 1799 Yiwei. It is estimated that the production-side productivity index tfpch of Taiwan-listed biotech companies is positively related to its stock price.